172 related articles for article (PubMed ID: 24053899)
1. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
[TBL] [Abstract][Full Text] [Related]
3. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
4. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
[TBL] [Abstract][Full Text] [Related]
5. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
[TBL] [Abstract][Full Text] [Related]
6. Activin Receptor-like kinase 1: a novel anti-angiogenesis target from TGF-β family.
Vecchia L; Olivieri C; Scotti C
Mini Rev Med Chem; 2013 Aug; 13(10):1398-406. PubMed ID: 23815578
[TBL] [Abstract][Full Text] [Related]
7. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.
Jonker L
Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424
[TBL] [Abstract][Full Text] [Related]
8. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex.
Townson SA; Martinez-Hackert E; Greppi C; Lowden P; Sako D; Liu J; Ucran JA; Liharska K; Underwood KW; Seehra J; Kumar R; Grinberg AV
J Biol Chem; 2012 Aug; 287(33):27313-25. PubMed ID: 22718755
[TBL] [Abstract][Full Text] [Related]
9. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K
J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae.
Santibanez JF; Blanco FJ; Garrido-Martin EM; Sanz-Rodriguez F; del Pozo MA; Bernabeu C
Cardiovasc Res; 2008 Mar; 77(4):791-9. PubMed ID: 18065769
[TBL] [Abstract][Full Text] [Related]
11. Activin receptor inhibitors--dalantercept.
Gupta S; Gill D; Pal SK; Agarwal N
Curr Oncol Rep; 2015 Apr; 17(4):14. PubMed ID: 25708802
[TBL] [Abstract][Full Text] [Related]
12. Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells.
Yao Y; Zebboudj AF; Torres A; Shao E; Boström K
Cardiovasc Res; 2007 May; 74(2):279-89. PubMed ID: 17074310
[TBL] [Abstract][Full Text] [Related]
13. ALK1 as an emerging target for antiangiogenic therapy of cancer.
Cunha SI; Pietras K
Blood; 2011 Jun; 117(26):6999-7006. PubMed ID: 21467543
[TBL] [Abstract][Full Text] [Related]
14. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.
Mitchell D; Pobre EG; Mulivor AW; Grinberg AV; Castonguay R; Monnell TE; Solban N; Ucran JA; Pearsall RS; Underwood KW; Seehra J; Kumar R
Mol Cancer Ther; 2010 Feb; 9(2):379-88. PubMed ID: 20124460
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
Bhatt RS; Atkins MB
Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
[TBL] [Abstract][Full Text] [Related]
16. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P
J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the ALK1 ligands, BMP9 and BMP10.
Li W; Salmon RM; Jiang H; Morrell NW
Biochem Soc Trans; 2016 Aug; 44(4):1135-41. PubMed ID: 27528761
[TBL] [Abstract][Full Text] [Related]
18. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
19. The role of angiogenesis in solid tumours: an overview.
Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
[TBL] [Abstract][Full Text] [Related]
20. Remodeling retinal neovascularization by ALK1 gene transfection in vitro.
Li B; Yin W; Hong X; Shi Y; Wang HS; Lin SF; Tang SB
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4553-60. PubMed ID: 18829861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
